Skip to content

Randomized Controlled Trial of Aromatherapy Combined with Transcranial Direct Current Stimulation for Post-Stroke Depression Comorbid with Sleep Disorders

Application of Aromatherapy Combined with Transcranial Direct Current Stimulation in the Treatment of Post-Stroke Depression Comorbid with Sleep Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113247
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-12-20
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Observation Group:Transcranial Direct Current Stimulation
Control Group:Transcranial Direct Current Stimulation Combined with Aromatherapy

Sponsors

Shandong Second Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria outlined in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023) and the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Hemorrhage (2019), and is confirmed by cranial CT or MRI; 2. Meet the diagnostic criteria for depression secondary to other medical conditions in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed as PSD, with Hamilton Depression Rating Scale-17 score >7 points; Pittsburgh Sleep Quality Index score >=7 points; 3. Be conscious and able to communicate verbally normally; 4. Have developed emotional disturbances after the stroke event; 5. Be aged 18 years < age <= 80 years; 6. Have not received antidepressant medication treatment; 7. Voluntarily participate in this study and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Critical condition deemed unsuitable for treatment by medical evaluation; 2. Allergy/aversion to aromatic scents; 3. Severe concomitant dysfunction of vital organs, including heart, liver, kidneys, or lungs; 4. Presence of contraindications for tDCS.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;Pittsburgh Sleep Quality Index;

Secondary

MeasureTime frame
Self-Rating Depression Scale;Functional near-infrared spectroscopy;

Countries

China

Contacts

Public ContactTengteng Cui

Shandong Second Medical University

ctt904427100@163.com+86 198 6140 1810

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026